Fulcrum TherapeuticsFULC
About: Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Employees: 89
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
1,798% more call options, than puts
Call options by funds: $36.5M | Put options by funds: $1.92M
73% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 26
4.94% more ownership
Funds ownership: 99.34% [Q1] → 104.28% (+4.94%) [Q2]
3% less funds holding
Funds holding: 125 [Q1] → 121 (-4) [Q2]
11% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 35
31% less capital invested
Capital invested by funds: $581M [Q1] → $402M (-$179M) [Q2]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
RBC Capital Gregory Renza 56% 1-year accuracy 45 / 80 met price target | 14%upside $4 | Sector Perform Downgraded | 13 Sept 2024 |
HC Wainwright & Co. Andrew Fein 46% 1-year accuracy 81 / 176 met price target | 14%upside $4 | Neutral Downgraded | 13 Sept 2024 |
Leerink Partners Joseph Schwartz 75% 1-year accuracy 6 / 8 met price target | 14%upside $4 | Market Perform Downgraded | 12 Sept 2024 |
B of A Securities Tazeen Ahmad 46% 1-year accuracy 13 / 28 met price target | 43%downside $2 | Underperform Downgraded | 12 Sept 2024 |
Stifel Dae Gon Ha 75% 1-year accuracy 9 / 12 met price target | 15%downside $3 | Hold Downgraded | 12 Sept 2024 |
Financial journalist opinion
Based on 51 articles about FULC published over the past 30 days